ArticleJournal of clinical laboratory analysis2020
Procalcitonin as a prognostic marker of patients with acute ischemic stroke.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Effect of Cilostazol in the Expression of Biomarkers and Neurological Outcome Following Experimentally Induced Cerebrovascular Accident-Experimental Protocol.Neurology international · 2025Article
- Advances in development of biomarkers for brain damage and ischemia.Molecular biology reports · 2024Review
- Body fluids biomarkers associated with prognosis of acute ischemic stroke: progress and prospects.Future science OA · 2024Review
- Machine learning-based prediction of clinical outcomes after first-ever ischemic stroke.Frontiers in neurology · 2023Article
- Value of inflammatory mediator profiles and procalcitonin in predicting postoperative infection in patients with hypertensive cerebral hemorrhage.World journal of clinical cases · 2022Article
- Acute Inflammation in Cerebrovascular Disease: A Critical Reappraisal with Focus on Human Studies.Life (Basel, Switzerland) · 2021Review
- Correlation analysis between serum procalcitonin and infarct volume in young patients with acute cerebral infarction.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Article
- Procalcitonin as a prognostic marker of patients with acute ischemic stroke.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe information on mortality after an acute stroke patient is still limited.
objectivesThe aim of this study was to investigate the prognostic potential of procalcitonin (PCT) serum levels in acute ischemic stroke.
methodsA total of 748 patients were enrolled in this study. Prognostic potential of PCT was evaluated by Kaplan-Meier analysis and multivariable Cox hazard regression analyses.
resultsProcalcitonin levels were found to be significantly higher in acute ischemic stroke patients who died in 30 days than those who survived. Univariate logistic regression analysis showed that PCT was significantly associated with 30-day mortality, and Cox regression analysis revealed that PCT was a strong predictor of 30-day overall mortality. Kaplan-Meier analysis revealed that overall cumulative 30-day mortality was significantly higher in those with PCT levels >1.5 ng/mL when compared to those with PCT levels <1.5 ng/mL.
conclusionsProcalcitonin is a significant independent prognostic marker of 30-day mortality after the one set of acute ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.